PMID- 34672813
OWN - NLM
STAT- MEDLINE
DCOM- 20220516
LR  - 20220516
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 37
IP  - 4
DP  - 2022 May
TI  - Laryngeal Squamous Cell Carcinoma: Clinical Significance and Potential Mechanism 
      of Cell Division Cycle 45.
PG  - 300-312
LID - 10.1089/cbr.2020.4314 [doi]
AB  - Background: Cell division cycle 45 (CDC45) plays an important role in the 
      occurrence and development of numerous carcinomas, but its effect in laryngeal 
      squamous cell carcinoma (LSCC) remains unclear. Materials and Methods: The 
      messenger RNA and protein expression levels of CDC45 in LSCC were evaluated with 
      a t test and the standard mean difference (SMD). The ability of CDC45 expression 
      to distinguish the LSCC was assessed through receiver operating characteristic 
      (ROC) curves. Gene set enrichment analysis (GSEA), protein-protein interaction, 
      public databases, and online tools were used to explore the potential molecular 
      mechanism of CDC45 in LSCC. Results: A high expression of CDC45 was identified in 
      LSCC (SMD = 2.61, 95% confidence interval [1.62-3.61]). Through ROC curves, the 
      expression of CDC45 makes it feasible to distinguish the LSCC group from the 
      non-LSCC counterpart. CDC45 was relevant to the progression-free interval of LSCC 
      patients (log-rank p = 0.03). GSEAs show that CDC45 is related to the cell cycle. 
      CDC45, CDC6, KIF2C, and AURKB were identified as hub genes of LSCC. E2F1 may be 
      the regulatory transcription factor of CDC45. Conclusions: High expression of 
      CDC45 likely demonstrates carcinogenic effects in LSCC, and CDC45 is a potential 
      target in screening and treatment of LSCC.
FAU - Li, Guo-Sheng
AU  - Li GS
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Yang, Lin-Jie
AU  - Yang LJ
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Chen, Gang
AU  - Chen G
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Huang, Su-Ning
AU  - Huang SN
AD  - Department of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, 
      P.R. China.
FAU - Fang, Ye-Ying
AU  - Fang YY
AD  - Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical 
      University, Nanning, P.R. China.
FAU - Huang, Wei-Jian
AU  - Huang WJ
AD  - Department of Pathology, Redcross Hospital of Yulin, Yulin, P.R. China.
FAU - Lu, Wei
AU  - Lu W
AD  - Department of Pathology, Nanning Second People's Hospital, Third Affiliated 
      Hospital of Guangxi Medical University, Nanning, P.R. China.
FAU - He, Juan
AU  - He J
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Liu, He-Chuan
AU  - Liu HC
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Li, Lin-Yi
AU  - Li LY
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
FAU - Mo, Bin-Yu
AU  - Mo BY
AD  - Department of Otolaryngology, Liuzhou People's Hospital, Liuzhou, P.R. China.
FAU - Lu, Hui-Ping
AU  - Lu HP
AD  - Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 
      Nanning, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20211021
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
SB  - IM
MH  - *Carcinoma, Squamous Cell/pathology
MH  - Cell Cycle/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - *Head and Neck Neoplasms/genetics
MH  - Humans
MH  - *Laryngeal Neoplasms/genetics/metabolism/pathology
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
OTO - NOTNLM
OT  - RNA-sequencing
OT  - cell division cycle 45
OT  - gene microarray
OT  - immunohistochemistry
OT  - laryngeal squamous cell carcinoma
OT  - tissue microarray
EDAT- 2021/10/22 06:00
MHDA- 2022/05/17 06:00
CRDT- 2021/10/21 20:40
PHST- 2021/10/22 06:00 [pubmed]
PHST- 2022/05/17 06:00 [medline]
PHST- 2021/10/21 20:40 [entrez]
AID - 10.1089/cbr.2020.4314 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2022 May;37(4):300-312. doi: 10.1089/cbr.2020.4314. 
      Epub 2021 Oct 21.